The Clinical Protocol, Data Management and Informatics (CPDMI) Shared Resource administrates clinical oncology research at the University of New Mexico (UNM) Cancer Center under the supervision of the Clinical Research Committee. The Medical Director of the CPDMI is D. Jones, who has extensive experience in clinical oncology research, and the Executive Director is T. Stewart. This Shared Resource has a current budget (FY2008/9) of $1.3 million. The CPDMI consists of 1 Medical Director, 1 Executive Director, 1 Regulatory Manager, 1 Quality Assurance Manager, 1 Database Administrator, 4 regulatory coordinators, 2 administrative assistants, 1 human protection specialists, and 1 Program Manager/accountant. The CPDMI includes a clinical informatics effort led by Kroth, which has 4 FTE, and a clinical trials imaging effort led by Eberhardt. The major goal of this Shared Resource is to provide support of the clinical trial process, including implementing and regulating trials, and providing a centralized clinical trial database, investigational pharmacy support, financial accounting, data safety monitoring, and quality assurance. This Shared Resource also assists physician investigators in the design and subsequent conduct of clinical trials. It performs all regulatory reporting and quality assurance needed to comply with Good Clinical Practice in the performance of clinical trials. The CPDMI has created Standardized Operating Procedures for all its activities, including training of all new faculty and staff. In FY2008/9, the CPDMI Shared Resource administrated 327 Cancer Center protocols, of which 114 were therapeutic/interventional trials. These therapeutic trials are also open within the New Mexico Cancer Care Alliance, the consortium of community oncologists affiliated with the UNM Cancer Center. At UNM Cancer Center outpatient clinics, 2640 new cancer patients (Summary 3) were treated in fiscal year 2009, and there were 443 accruals to therapeutic trials (17% of new patients), with an additional 101 therapeutic accruals supervised by the CPDMI at the Alliance affiliate sites. Accruals to all types of trials using the CPDMI were 1241 in fiscal year 2009. Of patients accrued to therapeutic clinical trials, 83% were women, 7% were Native Americans, and 44% were Hispanics. The UNM Cancer Center patient population had 56% women, 11% Native Americans, and 34% Hispanics. Additionally, the CPDMI reviewed 137 subject records as part of internal audits at UNM Cancer Center and affiliate sites.

Public Health Relevance

A major goal of the UNM Cancer Center is to develop new treatments for cancer patients. These new treatments must be tested using clinical research. This Shared Resource is responsible for administrating the clinical trials of the UNM Cancer Center. This administration of the clinical research enterprise implements and regulates clinical trials, and provides a centralized clinical trial database, investigational pharmacy support, financial accounting, data safety monitoring, and quality assurance. These elements are essential for testing new cancer treatments.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA118100-10
Application #
8723079
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
10
Fiscal Year
2014
Total Cost
$154,108
Indirect Cost
Name
University of New Mexico Health Sciences Center
Department
Type
DUNS #
829868723
City
Albuquerque
State
NM
Country
United States
Zip Code
87131
Flook, Adam M; Yang, Jianquan; Miao, Yubin (2014) Substitution of the Lys linker with the ?-Ala linker dramatically decreased the renal uptake of 99mTc-labeled Arg-X-Asp-conjugated and X-Ala-Asp-conjugated ?-melanocyte stimulating hormone peptides. J Med Chem 57:9010-8
Davies, Suzy; Holmes, Anna; Lomo, Lesley et al. (2014) High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer. Int J Gynecol Pathol 33:402-10
Wu, Yang; Tapia, Phillip H; Jarvik, Jonathan et al. (2014) Real-time detection of protein trafficking with high-throughput flow cytometry (HTFC) and fluorogen-activating protein (FAP) base biosensor. Curr Protoc Cytom 67:Unit 9.43.
Morris, K T; Khan, H; Ahmad, A et al. (2014) G-CSF and G-CSFR are highly expressed in human gastric and colon cancers and promote carcinoma cell proliferation and migration. Br J Cancer 110:1211-20
Vaughan, Roger A; Gannon, Nicholas P; Garcia-Smith, Randi et al. (2014) ?-alanine suppresses malignant breast epithelial cell aggressiveness through alterations in metabolism and cellular acidity in vitro. Mol Cancer 13:14
Lu, Jie; Hathaway, Helen J; Royce, Melanie E et al. (2014) Introduction of D-phenylalanine enhanced the receptor binding affinities of gonadotropin-releasing hormone peptides. Bioorg Med Chem Lett 24:725-30
Campen, Matthew J; Paffett, Michael L; Colombo, E Sage et al. (2014) Muscle RING finger-1 promotes a maladaptive phenotype in chronic hypoxia-induced right ventricular remodeling. PLoS One 9:e97084
Yang, Jianquan; Flook, Adam M; Feng, Changjian et al. (2014) Linker modification reduced the renal uptake of technetium-99m-labeled Arg-Ala-Asp-conjugated alpha-melanocyte stimulating hormone peptide. Bioorg Med Chem Lett 24:195-8
Hill, Jeff W; Thompson, Jeffrey F; Carter, Mark B et al. (2014) Identification of isoxsuprine hydrochloride as a neuroprotectant in ischemic stroke through cell-based high-throughput screening. PLoS One 9:e96761
Scaling, Allison L; Prossnitz, Eric R; Hathaway, Helen J (2014) GPER mediates estrogen-induced signaling and proliferation in human breast epithelial cells and normal and malignant breast. Horm Cancer 5:146-60

Showing the most recent 10 out of 123 publications